21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
23:20 , Jul 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Prophylactic IL-33 could treat infections

DISEASE CATEGORY: Infectious disease INDICATION: Clostridium  Prophylactic treatment with IL-33 could reduce the severity of C. difficile infection. Colon biopsy levels of IL-33 protein were higher in six patients with C. difficile infection than in...
23:59 , Jun 28, 2019 |  BioCentury  |  Product Development

Why tissue-agnostic drug development needs NGS to go mainstream

Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable...
23:41 , Jun 28, 2019 |  BC Extra  |  Financial News

June 28 Financial Quick Takes: Karuna rises after IPO; plus Chi-Med, BeiGene and more

Karuna spikes in first-day trading on NASDAQ  PureTech Health plc (LSE:PRTC) portfolio company Karuna Therapeutics Inc. (NASDAQ:KRTX) climbed $4.02 (25%) to $20.02 Friday after raising $89.2 million through the sale of 5.6 million shares at...
21:57 , Jun 27, 2019 |  BC Innovations  |  Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
09:15 , Jun 27, 2019 |  BC Extra  |  Financial News

MODAG raises €12M series A to test approach to neurodegeneration

Six years after its formation, neurodegeneration company MODAG hopes to use its new €12 million ($13.7 million) series A round to test its disease-modifying approach to a rare Parkinsonian disorder via the company's first clinical...
21:05 , Jun 20, 2019 |  BC Extra  |  Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
20:01 , Jun 20, 2019 |  BC Innovations  |  Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
09:01 , Jun 19, 2019 |  BC Extra  |  Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....